Massive CML registry launches to reveal how TKIs really perform

NCT ID NCT07091019

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This registry will follow 1,000 adults with chronic-phase CML who are taking approved TKIs (like Gleevec or Tasigna) as their first or second treatment. Over 5 years, researchers will track side effects, treatment changes, and patient-reported experiences to understand how these drugs work in real-world settings, not just in clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tyrosine kinase inhibitors (TKIs) such as asciminib, bosutinib, dasatinib, imatinib, nilotinib
What this could lead to: If successful, this registry could provide clearer insights into how well different TKIs work and are tolerated in everyday medical practice, helping doctors and patients make more informed treatment decisions.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care and reporting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA - CHRONIC PHASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myeloid, Chronic-Phase

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOGENOUS LEUKEMIA - CHRONIC PHASE

Contacts and locations

Locations

Avera Cancer
RECRUITING

Sioux Falls, South Dakota, 57105, United States
Baylor Scott and White Research
RECRUITING

Temple, Texas, 76502, United States
Cancer Care Specialists of Central Illinois
RECRUITING

Decatur, Illinois, 62526, United States
Fred Hutchinson Cancer Research Center
RECRUITING

Seattle, Washington, 98109-1024, United States
Lundquist Inst BioMed at Harbor
RECRUITING

Torrance, California, 90509-2910, United States
MultiCare Health System Institute
RECRUITING

Tacoma, Washington, 98405, United States
NY Cancer and Blood Specialists
RECRUITING

East Setauket, New York, 11733, United States
Northwest Medical Specialties
RECRUITING

Tacoma, Washington, 98405, United States
Oregon Oncology Specialists Salem
RECRUITING

Salem, Oregon, 97301, United States
SUNY Upstate Medical University
RECRUITING

Syracuse, New York, 13210, United States
Sacred Heart Medical Oncology
RECRUITING

Pensacola, Florida, 32504, United States
St Agnes Hospital
RECRUITING

Baltimore, Maryland, 21229, United States
Stamford Hospital
RECRUITING

Stamford, Connecticut, 06902, United States
Stockton Hematology Oncology Medical Group Inc
RECRUITING

Stockton, California, 95204, United States
Tri-County Hematology and Oncology Associates
RECRUITING

Canton, Ohio, 44718, United States
Truman Medical Center
RECRUITING

Kansas City, Missouri, 64108, United States
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35233-0271, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.